Gastric cancer (GC) remains challenging to treat clinically owing to poor tumortargeting performance, systemic toxicity and frequent chemoresistance. Herein, we constructed folic acidantibody(FA)functionalized vincristineloaded nanoliposomes (FAVCRMLs) for targeted gastric cancer therapy. The spherical nanoparticles had a mean size of 241.47.6nm and zeta potential of 38.57.9mV, with encapsulation efficiency of 93.720.48% and drugloading content of 10.370.69%. Approximately 88% of vincristine was released under acidic conditions in a pHdependent manner. These liposomes exhibited satisfactory biocompatibility and enhanced cellular uptake in GC cells relative to free vincristine and nontargeted VCRMLs. Invivo assays showed an 85% tumorsuppression rate, 9% of tumorbearing nude mice survived by day 71. In summary, FAVCRMLs represent an effective targeted nanotherapeutic agent against gastric cancer.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: